Juan José Grau1, Miguel Caballero, Eugenia Verger, Mariano Monzó, Jose Luís Blanch. 1. Oncology Department, Institut Clinic de Malalties Hemato-Oncologiques, University of Barcelona, Augusto Pi i Sunyer Memorial Institute for Biomedical Research, Hospital Clinic of Barcelona, Villarroel St 170, Barcelona, Spain.
Abstract
CONCLUSIONS: Weekly paclitaxel may be an active and well tolerated chemotherapy regimen for patients with platin-resistant advanced head and neck cancer. OBJECTIVES: Weekly paclitaxel should be an active and well tolerated regimen for palliative treatment of platin-resistant patients with recurrent or metastatic carcinoma of the head and neck. We analyzed the antitumor activity and toxicity profile. PATIENTS AND METHODS: Sixty consecutive patients with advanced head and neck cancer were treated with 1 h infusion of paclitaxel, 80 mg/m(2) weekly, for 6 consecutive weeks. Patients who showed disease response or disease stabilization continued until progression of disease. RESULTS: A total of 719 doses of paclitaxel were administered to the 60 patients. No complete response was observed. Partial response and stable disease were observed in 26 (43.3%) and 9 (15%) patients, respectively. Median time to tumor progression for patients who responded to therapy was 6.2 months (SD=1.3; 95% CI, 3.7-8.6) and the overall median survival in this group of patients was 8.5 months (SD=1.4; 95% CI, 5.7-11.2). The main toxic effects were leukopenia (26.6%), anemia (43.3%), fatigue (37.4%), alopecia (18.7%), rash/desquamation (13.3%), and thrombophlebitis (6.8%).
CONCLUSIONS: Weekly paclitaxel may be an active and well tolerated chemotherapy regimen for patients with platin-resistant advanced head and neck cancer. OBJECTIVES: Weekly paclitaxel should be an active and well tolerated regimen for palliative treatment of platin-resistant patients with recurrent or metastatic carcinoma of the head and neck. We analyzed the antitumor activity and toxicity profile. PATIENTS AND METHODS: Sixty consecutive patients with advanced head and neck cancer were treated with 1 h infusion of paclitaxel, 80 mg/m(2) weekly, for 6 consecutive weeks. Patients who showed disease response or disease stabilization continued until progression of disease. RESULTS: A total of 719 doses of paclitaxel were administered to the 60 patients. No complete response was observed. Partial response and stable disease were observed in 26 (43.3%) and 9 (15%) patients, respectively. Median time to tumor progression for patients who responded to therapy was 6.2 months (SD=1.3; 95% CI, 3.7-8.6) and the overall median survival in this group of patients was 8.5 months (SD=1.4; 95% CI, 5.7-11.2). The main toxic effects were leukopenia (26.6%), anemia (43.3%), fatigue (37.4%), alopecia (18.7%), rash/desquamation (13.3%), and thrombophlebitis (6.8%).
Authors: U Hillen; M Ulrich; M Alter; J C Becker; R Gutzmer; U Leiter; A Lonsdorf; A Messerschmidt; C Ulrich Journal: Hautarzt Date: 2014-07 Impact factor: 0.751
Authors: Aaron E Sosa; Juan J Grau; Luis Feliz; Verónica Pereira; Diego Alcaraz; Carmen Muñoz-García; Miguel Caballero Journal: Eur Arch Otorhinolaryngol Date: 2013-05-04 Impact factor: 2.503
Authors: Thomas Chevalier; Amaury Daste; Esmaa Saada-Bouzid; Anderson Loundou; Florent Peyraud; Tiphaine Lambert; Christophe Le Tourneau; Frédéric Peyrade; Charlotte Dupuis; Marc Alfonsi; Jérôme Fayette; Juliette Reure; Florence Huguet; Nicolas Fakhry; Clémence Toullec; Sébastien Salas Journal: Cancer Med Date: 2021-05-25 Impact factor: 4.452
Authors: I Pajares Bernad; J Martínez Trufero; L Calera Urquizu; R A Pazo Cid; A Cebollero de Miguel; M J Agustin; M Lanzuela; A Antón Journal: Clin Transl Oncol Date: 2017-01-24 Impact factor: 3.340